Group 1 - The core announcement is that Lexin Technology will start market-making trading services for its stocks on the Sci-Tech Innovation Board, effective from November 11, 2025 [2] - The trading will be conducted by GF Securities Co., Ltd., indicating a strategic partnership that may enhance liquidity and trading volume for Lexin Technology's shares [2] - The stock code for Lexin Technology on the Sci-Tech Innovation Board is 688018, which is relevant for investors and market participants [2]

Group 1 - The core viewpoint of the news is the significant asset restructuring plan announced by China International Capital Corporation (CICC), Dongxing Securities, and Xinda Securities, which aims for a share swap merger to enhance synergy and competitive advantages [1] - As of December 18, 2025, the Guozheng Securities Leading Index (399437) has decreased by 1.08%, with mixed performance among constituent stocks, including a 10% limit-up for Dongxing Securities and a 3.96% increase for CICC [1] - The trading volume remains active, fluctuating between 1.7 trillion to 2.0 trillion yuan, with a financing balance stabilizing at 2.48 trillion yuan, indicating a positive long-term trend in the market despite short-term volatility [1] Group 2 - The China Securities Regulatory Commission (CSRC) chairman mentioned optimizing evaluation indicators for quality institutions, moderately expanding capital space and leverage limits, and shifting from price competition to value competition [2] - Major brokerages have a low equity fund position of only 0.62%, with large brokerages having an average price-to-book (PB) ratio of 1.46x, indicating potential for improvement in leverage and profitability [2] - The top ten weighted stocks in the Guozheng Securities Leading Index account for 79.05% of the index, highlighting the concentration of market performance among leading securities firms [2]

（文章来源：证券日报） 证券日报网讯 12月17日，茂莱光学发布公告称，根据《上海证券交易所科创板股票做市交易业务实施 细则》相关规定，经广发证券股份有限公司备案申请，自2025年11月11日起，广发证券股份有限公司对 科创板股票茂莱光学（股票代码：688502）开展做市交易业务。 ...

12月18日午后，银行股反弹，板块内全线飘红。上海银行涨近3%，苏州银行、厦门银行、杭州银行涨 超2%，建设银行、渝农商行、南京银行、江阴银行涨幅居前。 随着2026年日益临近，银行股的业绩走向与结构分化逻辑再次成为机构研报的核心议题。 作为"十五五"规划的开局之年，银行业的经营环境与投资逻辑将如何演变？对于投资者而言，机会藏于 何处？ 近期，多家券商密集发布年度展望，普遍认为在宏观政策托底、息差有望筑底以及存量风险持续缓释的 背景下，2026年上市银行整体业绩大概率将步入温和修复通道。 然而，几乎所有机构都同时强调，行业内部的结构性分化将成为未来一年的主旋律，马太效应加剧，具 备独特客户优势、负债成本管控能力或特定区域禀赋的银行，将有望领跑新一轮周期。 综合各家观点，一个明确的预期正在形成，即行业净息差有望在2026年触底并逐步趋稳。支撑这一判断 的共同逻辑在于，存款成本在监管引导与自然重定价下有改善空间，而资产端收益率的下行压力预计将 有所减缓。 机构普遍指出，这一改善过程将更利好于负债基础扎实、活期存款占比高的大型银行，以及部分存款成 本改善空间较大的中小银行。 业绩温和修复成共识，内部分化已成定局 对 ...

证券研究报告 金融 公募绩效考核优化，关注优质金融 华泰研究 2025 年 12 月 18 日│中国内地 行业月报 公募绩效考核优化，关注优质金融 25 年 11 月全市场发行理财产品 2631 份，环比+23.6%；公募基金新发份额 946 亿份，月环比+31%。12 月《基金管理公司绩效考核管理指引（征求意 见稿）》下发，强化长期业绩导向、提高强制跟投比例，并明确量化降薪问 责机制等，将基金公司及其核心投研人员的利益与投资者的长期利益深度绑 定。资本市场中长期稳步向上趋势不改，奠定资管产品发展基础。建议把握 优质个股，银行推荐零售及财富管理标杆招行 AH，财富管理战略地位提升 的宁波银行；券商推荐大财富管理产业链具备较强优势的广发 AH、东方 AH。 银行理财：存续规模微增，收益表现下行 根据基金业协会数据，截至 25Q2 末，券商资管规模为 6.14 万亿元，季度 环比+4%。2025 年 11 月新发份额 44.69 亿份，环比持平。从新发份额结构 上看，债券型占比最高，达 53.27%。 私募基金：存量规模环比增长，证券投资基金备案规模环比提升 根据基金业协会数据，截至 2025 年 10 月末，全 ...

Group 1 - The successful launch of the Resource 3-04 satellite using the Long March 4B rocket marks a significant achievement in China's space industry, with plans for reusable rockets like the Tianlong 3 and Long March 12A to conduct their maiden flights between December 2025 and early 2026, potentially accelerating industry development [1] - Dongwu Securities highlights that recent breakthroughs in reusable rocket technology signify a shift towards "low-cost, high-reusability" in China's aerospace sector, which will benefit related industries such as aerospace manufacturing, new materials, and satellite applications in the short term, while positioning China as a strong player in the global aerospace landscape in the long term [1] - The commercial space industry in China is experiencing a dual boost from policy and technology, with the National Space Administration's action plan for 2025-2027 aiming for significant industry growth and efficient collaboration, alongside support for low-orbit satellites in the IoT sector [2] Group 2 - West Securities expresses optimism about the low-orbit satellite sector entering a growth phase, emphasizing that breakthroughs in rocket capacity are crucial for the commercial space industry's transformation, with new rockets like Zhuque 3 expected to facilitate large-scale industrialization [2] - The development of AI technology is enhancing spatial computing and satellite data processing capabilities, with advancements in large model capabilities showing promise in image recognition and remote sensing, potentially leading to real-time data analysis and decision-making in commercial space applications [3] - The satellite ETF from Guangfa has seen a strong performance, with a 4.76% increase in the China Satellite Industry Index and a cumulative rebound of over 24% since November 21, indicating positive market sentiment towards satellite-related stocks [3][4] Group 3 - The China Satellite Industry Index focuses on the upstream satellite industry, comprising 50 listed companies involved in satellite manufacturing, launching, communication, navigation, and remote sensing, reflecting the core competitiveness and overall development of China's satellite industry [4] - The index includes key players in various segments: upstream satellite manufacturing and launching (e.g., Aerospace Electronics, China Satellite), midstream ground equipment and operations (e.g., China Satellite, China Satcom), and downstream application services (e.g., China Satcom, Zhongke Xingtou) [4]

12月18日，大消费板块持续走高，零售、服装、食品饮料方向领涨，百大集团走出6连板，利群股份3连 板，中央商场、上海九百、九牧王、皇氏集团、浪莎股份涨停。 消息面上，中央财办有关负责同志表示，扩大内需是明年排在首位的重点任务，明年要把握消费的结构 性变化，从供需两侧发力提振消费。 回顾近期，与促进消费、提振内需相关的政策密集出台，在提振居民消费预期同时，也给大消费板块行 情向好提供了助力。 业内人士认为，延续并扩大直接补贴及消费贷贴息、改善物价等，有望成为短期内值得期待的扩消费政 策；从投资角度出发，消费行业呈现底部特征，基本面触底修复构成股价"催化剂"，具备规模效应且业 绩弹性突出的连锁餐饮与新茶饮企业、赛事运营与相关服务领域的体育公司、具备稀缺IP价值并能持续 转化粉丝经济的演艺运营商等细分标的值得关注。 政策红利不断释放 在中国银河证券首席经济学家、研究院院长章俊看来，未来经济工作需要促进形成更多由内需主导、消 费拉动、内生增长的经济发展模式，在财政支出方向上，"以旧换新"政策有望延续并更多向服务消费领 域倾斜，2026年推动更多资金资源投资于人、服务民生这一政策导向或会继续强化。 临近年底消费旺季，从 ...

Core Viewpoint - Chengdu Maikang Biological Technology Co., Ltd. (hereinafter referred to as Maikang Bio) has completed its IPO counseling filing with the Sichuan Securities Regulatory Bureau, aiming for A-share listing, with China International Capital Corporation as the counseling institution [1]. Group 1: Company Overview - Maikang Bio was established on April 29, 2016, with a registered capital of 37.261289 million yuan [1]. - The company is primarily engaged in the research, development, production, and commercialization of innovative vaccines and novel adjuvants, recognized as a national high-tech enterprise and a "little giant" enterprise in Sichuan Province [1][2]. - The controlling shareholder is Chengdu Qianding Enterprise Management Consulting Co., Ltd., which directly holds 22.09% of the company's shares [3]. Group 2: Product Development - Maikang Bio has diversified its product development pipeline targeting infectious diseases, allergic diseases, and oncology, including several preventive vaccines for major infectious diseases and therapeutic vaccines for HPV infections, allergic diseases, and cancer, with three projects currently in clinical trial stages [2]. - To advance the industrialization of novel adjuvants and human vaccines, the company has nearly completed the construction of an innovative vaccine production platform and has initiated the establishment of an industrialization base [2]. Group 3: Leadership and Expertise - The chairman and general manager of Maikang Bio is Chen Dexiang, who holds a Ph.D. in immunology from Mississippi State University and has over 30 years of experience in vaccine and adjuvant development at Pfizer, Novartis, and PATH [4][7]. - Chen has led numerous major international public health projects funded by international organizations, foundations, and national governments, with over 20 vaccine development projects resulting in multiple products launched globally [4][7]. - He has published more than 60 academic papers related to vaccines in top-tier journals such as Science and Nature Medicine [4][7].

Group 1 - The core viewpoint of the report is that 聚水潭 (Jushuitan) is positioned as a leading collaborative platform in the e-commerce SaaS ERP sector, providing cloud-based ERP solutions to address pain points faced by e-commerce merchants in multi-platform operations [1] - The company is expected to achieve revenues of 1.14 billion, 1.39 billion, and 1.66 billion yuan for the years 2025, 2026, and 2027 respectively, with net profits of 70 million, 350 million, and 520 million yuan for the same years [1] - The report assigns a reasonable valuation multiple of 12x PS for 2026, resulting in a target price of 42.09 HKD per share, with a "Buy" rating [1] Group 2 - The e-commerce SaaS ERP market is characterized as small yet beautiful, with the ERP system effectively integrating core operational processes within the e-commerce industry, addressing challenges such as cross-platform store management and inventory management [2] - The market for e-commerce SaaS ERP is expected to maintain a high growth rate as it expands its business scenarios and integrates more collaborative functions [2] Group 3 - 聚水潭 holds a solid leading position in the e-commerce SaaS ERP industry, with a market share of 24.4% in 2024, significantly ahead of competitors [3] - The company's financial metrics are improving, with a LTV/CAC ratio reaching 9.3 in 2024, indicating a strong sales and product system [3] - The net customer revenue retention rate for 2024 is 115%, showcasing the company's effectiveness in customer retention and increasing customer spending [3] Group 4 - The company is actively expanding internationally, having established a subsidiary in Thailand and plans to explore opportunities in Southeast Asia, Europe, Latin America, and the Middle East [4] - Leveraging its customer resources accumulated in the e-commerce SaaS ERP field, the company aims to enhance its value-added software business, potentially opening new growth avenues [4]

Group 1 - The core viewpoint of the report is that 聚水潭 is positioned as a leading collaborative platform in the e-commerce SaaS ERP sector, providing cloud-based ERP solutions to address the pain points of e-commerce merchants in multi-platform operations [2] - The company is expected to achieve revenue of 1.14 billion, 1.39 billion, and 1.66 billion yuan, and net profit of 70 million, 350 million, and 520 million yuan for the years 2025 to 2027 respectively [1] - The company is assigned a reasonable valuation multiple of 12x PS for 2026, leading to a target price of 42.09 HKD per share, with a "Buy" rating [1] Group 2 - The e-commerce SaaS ERP market is characterized as small yet beautiful, with the ERP system effectively integrating core operational processes to solve issues related to cross-platform store management and inventory management [3] - 聚水潭 holds a significant market share of 24.4% in the e-commerce SaaS ERP industry in 2024, demonstrating a strong competitive position [4] - The company has a customer retention rate of 115% in 2024, indicating strong performance in customer retention and increased spending [4] Group 3 - The company is actively expanding internationally, having established a subsidiary in Thailand and plans to explore opportunities in Southeast Asia, Europe, Latin America, and the Middle East [5] - 聚水潭 aims to leverage its existing customer resources in the e-commerce SaaS ERP field to further develop its value-added software business, potentially opening new growth avenues [5]